Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors-Reference-Cited by-同舟云学术

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

Published:2020-12 Issue:6 Volume:78 Page:822-830
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Fizazi Karim^ORCID,Drake Charles G.,Beer Tomasz M.,Kwon Eugene D.,Scher Howard I.,Gerritsen Winald R.,Bossi Alberto,den Eertwegh Alfons J.M. van,Krainer Michael,Houede Nadine^ORCID,Santos Ricardo,Mahammedi Hakim,Ng Siobhan,Danielli Riccardo,Franke Fabio A.,Sundar Santhanam,Agarwal Neeraj,Bergman André M.,Ciuleanu Tudor E.,Korbenfeld Ernesto,Sengeløv Lisa,Hansen Steinbjorn,McHenry M. Brent,Chen Allen,Logothetis Christopher

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Urology

Reference39 articles.

1. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer consensus Conference APCCC 2017;Gillessen;Eur Urol,2018

2. Prostate cancer: ESMO consensus conference guidelines 2012;Horwich;Ann Oncol,2013

3. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European expert consensus panel;Fitzpatrick;Eur J Cancer,2014

4. Inhibitors of the PD-1 pathway in tumor therapy;LaFleur;J Immunol,2018

5. Immunotherapy for castration-resistant prostate cancer: progress and new paradigms;Quinn;Urol Oncol,2015

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ELAVL1 regulates PD-L1 mRNA stability to disrupt the infiltration of CD4-positive T cells in prostate cancer;Neoplasia;2024-11

2. Neoadjuvant androgen deprivation therapy with or without Fc-enhanced non-fucosylated anti-CTLA-4 (BMS-986218) in high risk localized prostate cancer: a randomized phase 1 trial;2024-09-11

3. Nanomedicines in diagnosis and treatment of prostate cancers: an updated review;Frontiers in Bioengineering and Biotechnology;2024-08-21

4. Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a Syngeneic Model;Cancers;2024-08-14

5. Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance;Cancers;2024-08-08